Viewing Study NCT05904457


Ignite Creation Date: 2025-12-24 @ 6:33 PM
Ignite Modification Date: 2026-01-06 @ 2:12 AM
Study NCT ID: NCT05904457
Status: RECRUITING
Last Update Posted: 2023-06-15
First Post: 2023-06-06
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: A Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered Cancer
Sponsor: Asan Medical Center
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module